Literature DB >> 23094759

Transmission of angiosarcomas from a common multiorgan donor to four transplant recipients.

J Thoning1, Y Liu, C Bistrup, A Thomassen, C Borst, N Marcussen, M Tepel.   

Abstract

We describe the donor tumor transmission of metastatic angiosarcomas to four transplant recipients through transplantation of deceased-donor organs, i.e. kidneys, lung and liver, from an apparently unaffected common female multiorgan donor. Fluorescent in situ hybridization of angiosarcoma cells confirmed that the tumor was of female donor's origin in male kidney recipients. Recent literature associated increased urokinase-plasminogen-activator-receptor (uPAR) and plasma soluble urokinase-plasminogen-activator-receptor (suPAR) levels with metastatic malignancies. Now we found that, compared to baseline levels, both deceased-donor kidney recipients showed increased uPAR transcripts in mononuclear cells as well as increased plasma suPAR levels after the diagnosis of metastatic angiosarcomas, i.e. 4 months after donor tumor transmission. These results show an association of uPAR/suPAR in donor tumor transmission of metastatic angiosarcomas in humans. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23094759     DOI: 10.1111/j.1600-6143.2012.04301.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  2 in total

Review 1.  Renal Cancer in Recipients of Kidney Transplant.

Authors:  Prajwal Dhakal; Smith Giri; Krishmita Siwakoti; Supratik Rayamajhi; Vijaya Raj Bhatt
Journal:  Rare Tumors       Date:  2017-03-24

2.  Case Report: An Unusual Course of Angiosarcoma After Lung Transplantation.

Authors:  Saskia Bos; Liesbeth Daniëls; Lucienne Michaux; Isabelle Vanden Bempt; Sascha Vermeer; F J Sherida H Woei-A-Jin; Patrick Schöffski; Birgit Weynand; Raf Sciot; Sabine Declercq; Laurens J Ceulemans; Laurent Godinas; Geert M Verleden; Dirk E Van Raemdonck; Lieven J Dupont; Robin Vos
Journal:  Front Immunol       Date:  2022-01-03       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.